Sodium–glucose co-transporter-2 inhibitors

Lee, M. M.Y. , Docherty, K. F. and Jhund, P. S. (2022) Sodium–glucose co-transporter-2 inhibitors. In: Clark, A. L., Gardner, R. S. and McDonagh, T. A. (eds.) Oxford Textbook of Heart Failure (2 edn). Oxford University Press, pp. 637-644. ISBN 9780198766223 (doi: 10.1093/med/9780198766223.003.0051)

Full text not currently available from Enlighten.


This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have been very impressive with three large, undoubtedly positive results. These are the Randomized Aldactone Evaluation Study (RALES study); the Eplerenone Post-acute MI Heart failure Efficacy and Survival Study (EPHESUS) study; and the Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart failure (EMPHASIS-HF) study. Importantly, there are no neutral or negative studies for aldosterone blockade in HF-REF. As a result, all CHF guidelines recommend MRAs as third line drugs after angiotensin converting enzyme inhibitors (ACEIs) and beta-blockers.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Lee, Matthew and Docherty, Dr Kieran and Jhund, Professor Pardeep
Authors: Lee, M. M.Y., Docherty, K. F., and Jhund, P. S.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Publisher:Oxford University Press

University Staff: Request a correction | Enlighten Editors: Update this record